Clinical Trials
268 trialsCadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
CaboPoint
Ipsen
KEYNOTE-B61
Merck Sharp & Dohme LLC
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Skippy 1
Leiden University Medical Center
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
CABRAMET
Centre Leon Berard
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Swiss Cancer Institute
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Thomas Jefferson University
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
IL2HD
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
A-PREDICT
Institute of Cancer Research, United Kingdom
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
CALYPSO
Queen Mary University of London
ASSET
Duke University
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Tianjin Medical University Second Hospital
SELECT
Beth Israel Deaconess Medical Center
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
AcSé
UNICANCER
CHEERS
University Hospital, Ghent
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Mirati Therapeutics Inc.
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
IO-PAZ
Novartis
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Canadian Cancer Trials Group
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Endocyte
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Eastern Cooperative Oncology Group
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
Endocyte
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
MK-3475-427
Merck Sharp & Dohme LLC
CANTATA
Calithera Biosciences, Inc